Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT.

Sci Transl Med. 2019 Sep 4;11(508). pii: eaaw8828. doi: 10.1126/scitranslmed.aaw8828.

PMID:
31484791
2.

U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.

Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Walter M, Fraser IDC, Kulkarni A, Salomonis N, Komurov K, Boultwood J, Verma A, Starczynowski DT.

Nat Cell Biol. 2019 May;21(5):640-650. doi: 10.1038/s41556-019-0314-5. Epub 2019 Apr 22.

3.

TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis.

Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, Starczynowski DT.

Cell Rep. 2018 Jan 30;22(5):1250-1262. doi: 10.1016/j.celrep.2018.01.013.

4.

Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.

Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, Salamonis N, Geiger H, Zheng Y, Starczynowski DT.

Nat Immunol. 2017 Mar 22;18(4):474. doi: 10.1038/ni0417-474a. No abstract available.

5.

Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.

Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, Salomonis N, Geiger H, Zheng Y, Starczynowski DT.

Nat Immunol. 2017 Feb;18(2):236-245. doi: 10.1038/ni.3654. Epub 2016 Dec 26. Erratum in: Nat Immunol. 2017 Mar 22;18(4):474.

6.

IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.

Adams AK, Bolanos LC, Dexheimer PJ, Karns RA, Aronow BJ, Komurov K, Jegga AG, Casper KA, Patil YJ, Wilson KM, Starczynowski DT, Wells SI.

Oncotarget. 2015 Dec 22;6(41):43395-407. doi: 10.18632/oncotarget.6028.

Supplemental Content

Loading ...
Support Center